Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms

Completed

• Conditions: Myeloproliferative Disorders; Pulmonary Hypertension

• Registration Number: NCT02580903
• Lead Sponsor: Odense University Hospital

Brief Summary

This is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with Myeloproliferative Neoplasms and their prognosis.

All patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. All will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the European Cardiology Association.

All patients will be followed up for a total of five years to identify prognosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-01-31
• Study Start: 2015-02
• Study First Submitted QC: 2015-10-19
• Study First Posted: 2015-10-20
• Primary Completion: 2018-02
• Study Completion: 2020-02
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-15
• Last Update Posted: 2020-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Myeloproliferative Neoplasms (PV, ET, PMF according to WHO classification)

Read More

Exclusion Criteria

• Pregnancy
• Lack of informed consent
• Age < 18 years
• Cognitive dysfunctions

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of pulmonary hypertension at initial presentation and first echo	Initial recruitment

Secondary Outcome Measures

Name	Time	Method
Mortality	1 and 5 years
Incidence of pulmonary hypertension while under follow-up	5 years

Trial Locations

Locations (1)

Odense University Hospital; 🇩🇰 Odense, Denmark